Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Beauty Health (SKIN) EBITDA (2020 - 2026)

SkinHealth Systems has reported EBITDA over the past 6 years, most recently at -$7.8 million for Q4 2025.

  • Quarterly EBITDA rose 42.8% to -$7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.0 million through Dec 2025, up 87.88% year-over-year, with the annual reading at -$4.0 million for FY2025, 87.88% up from the prior year.
  • EBITDA was -$7.8 million for Q4 2025 at SkinHealth Systems, up from -$10.6 million in the prior quarter.
  • Over five years, EBITDA peaked at $31.3 million in Q1 2022 and troughed at -$216.7 million in Q3 2021.
  • The 5-year median for EBITDA is -$7.6 million (2023), against an average of -$23.7 million.
  • Year-over-year, EBITDA plummeted 10188.79% in 2021 and then skyrocketed 3901.47% in 2025.
  • A 5-year view of EBITDA shows it stood at -$20.6 million in 2021, then skyrocketed by 142.27% to $8.7 million in 2022, then plummeted by 184.06% to -$7.3 million in 2023, then tumbled by 84.97% to -$13.6 million in 2024, then surged by 42.8% to -$7.8 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's EBITDA are -$7.8 million (Q4 2025), -$10.6 million (Q3 2025), and $23.3 million (Q2 2025).